Intravenous thrombolytic therapy remains the guideline-recommended treatment to improve outcomes after acute ischemic stroke. However, the functional outcome among patients with acute ischemic stroke after receiving intravenous thrombolytic therapy is influenced by huge variety of factors, and this was the aim of our study to evaluate the outcome predictors of intravenous thrombolytic therapy in a sample of Egyptian patients with acute ischemic stroke. We enrolled 183 acute ischemic stroke patients who were treated with intravenous recombinant tissue plasminogen activator (IV rtPA) according to the last updated guidelines of American Heart Association and American Stroke Association (AHA/ASA) from February 2018 to February 2020; however, only 150 patients of them completed our study plan till the end. Data of study variables were collected, analyzed statistically and correlated with the functional outcome 3 months after receiving IV rtPA using the modified Rankin Scale (mRS). Good functional outcome was seen in 98 (65.3%) patients and poor functional outcome was seen in 52 (34.7%) patients. Multivariate analysis of the study variables was done to detect the significant independent predictors of the functional outcome. Atrial fibrillation (AF) (P value < 0.001*OR 6.28* (95% C.I)), hypertension (P value 0.001*OR 3.65*(95% C.I)), diabetes mellitus (DM) (P value 0.009*OR 2.805*(95% C.I)), increased National Institute of Health Stroke Scale (NIHSS) score 24 h after receiving IV rtPA (P value 0.003* OR 8.039* (95% C.I)), increased pulsatility index (PI) value in cerebral vessels at the same side of stroke lesion (P value 0.038* OR 42.48*(95% C.I)) were the significant independent predictors of poor functional outcome. On the other hand decreased NIHSS score 24 h after receiving IV rtPA (P value 0.003* OR 0.124*(95% C.I)), Normal value of PI in cerebral vessels at the same side of stroke lesion (P value 0.038* OR 42.48*(95% C.I)) were the significant independent predictors of good functional outcome. Intravenous thrombolytic therapy improves the functional outcome of acute ischemic stroke patients. Also, AF, hypertension, DM, NIHSS 24 h after receiving IV rtPA and PI could be used as independent predictors of the functional outcome.

中文翻译：

---

急性缺血性卒中患者静脉溶栓治疗的预后预测因素：埃及中心的经验

静脉溶栓治疗仍然是指南推荐的治疗方法，以改善急性缺血性卒中后的预后。然而，接受静脉溶栓治疗的急性缺血性卒中患者的功能结局受多种因素的影响，这就是我们研究的目的，旨在评估埃及急性缺血性脑卒中患者样本中静脉溶栓治疗的结局预测因素。中风。我们根据美国心脏协会和美国卒中协会 (AHA/ASA) 2018 年 2 月至 2020 年 2 月的最新指南纳入了 183 名接受静脉注射重组组织纤溶酶原激活剂 (IV rtPA) 治疗的急性缺血性卒中患者；然而，直到最后，他们中只有 150 名患者完成了我们的研究计划。收集了研究变量的数据，使用改良的 Rankin 量表 (mRS) 进行统计学分析并与接受 IV rtPA 3 个月后的功能结果相关联。98 名 (65.3%) 患者的功能结果良好，52 名 (34.7%) 患者的功能结果不佳。对研究变量进行多变量分析以检测功能结果的显着独立预测因子。心房颤动 (AF)（P 值 < 0.001*OR 6.28* (95% CI)）、高血压（P 值 0.001*OR 3.65*（95% CI））、糖尿病（DM）（P 值 0.009*OR 2.805* (95% CI))，在接受 IV rtPA 后 24 小时增加美国国立卫生研究院卒中量表 (NIHSS) 评分（P 值 0.003* 或 8.039*（95% CI）），增加脑血管搏动指数（PI）值中风病变的同侧（P 值 0.038* 或 42.48*（95% C. I)) 是不良功能结果的显着独立预测因子。另一方面，接受 IV rtPA 后 24 小时 NIHSS 评分降低（P 值 0.003* 或 0.124*（95% CI）），中风病变同侧脑血管 PI 的正常值（P 值 0.038* 或 42.48* (95% CI)) 是良好功能结果的重要独立预测因子。静脉溶栓治疗可改善急性缺血性卒中患者的功能结局。此外，AF、高血压、DM、接受 IV rtPA 和 PI 后 24 小时的 NIHSS 可用作功能结果的独立预测因子。I)) 是良好功能结果的重要独立预测因子。静脉溶栓治疗可改善急性缺血性卒中患者的功能结局。此外，AF、高血压、DM、接受 IV rtPA 和 PI 后 24 小时的 NIHSS 可用作功能结果的独立预测因子。I)) 是良好功能结果的重要独立预测因子。静脉溶栓治疗可改善急性缺血性卒中患者的功能结局。此外，AF、高血压、DM、接受 IV rtPA 和 PI 后 24 小时的 NIHSS 可用作功能结果的独立预测因子。